AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2018
Aug 7, 2018
34721_dirs_2018-08-07_6334d7ff-b934-413e-9109-28f232cb742e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-08-06
Reporting Person: Amado Rafael (President, R & D)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-08-06 | Option to purchase Ordinary Shares | $0.0013 | A | 678720 | Acquired | Ordinary Shares (678720) | Direct |
Footnotes
F1: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.29679 - GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 169,680 Ordinary Shares on August 6, 2019 and will be exercisable as to the remainder in annual installments of 169,680 Ordinary Shares on the sixth of each August from August 6, 2020 through August 6, 2022.
F3: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.